The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study

The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study

Elevated low-density lipoprotein (LDL) cholesterol is one of the leading causes of cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce LDL cholesterol levels with subsequent reductions in cardiovascular morbidity. Elevated aldosterone levels are also assoc...

Full description

Bibliographic Details
Main Authors: Elena Izkhakov, Yacov Shacham, Merav Serebro, Iris Yaish, Yonit Marcus, Gabi Shefer, Karen Tordjman, Yona Greenman, Naftali Stern, Tomer Ziv-Baran
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Journal of Clinical Medicine
Subjects:
PCSK9 inhibitors
aldosterone
cortisol
hypertension
Online Access:https://www.mdpi.com/2077-0383/10/11/2504

Internet

https://www.mdpi.com/2077-0383/10/11/2504

Similar Items